STAGE IVA PROSTATE CANCER AJCC V8

This study is for men with prostate cancer that has spread to other parts of the body. It compares standard drug therapy alone versus standard drug therapy plus either surgery to remove the prostate or radiation to the prostate. The goal is to see if adding local treatment helps …

This study tests whether adding the drug apalutamide to standard hormone therapy and radiation helps men with prostate cancer that has spread to lymph nodes after surgery. About 586 participants will receive either the usual treatment or the usual treatment plus apalutamide. The …

This study tests whether giving a drug called abemaciclib before a targeted radiation therapy (177Lu-PSMA-617) can make the radiation work better for men with advanced prostate cancer that has stopped responding to other treatments. About 30 participants will receive the combinat…

This study is for men with high-risk prostate cancer that hasn't spread far. It tests whether adding the drug niraparib to standard hormone therapy after radiation can keep the cancer from coming back longer. About 200 men will take part, and researchers will track cancer progres…

This study compares two different hormone therapy combinations for men with advanced prostate cancer who are also getting radiation. The goal is to see which combination causes less harm to the heart. About 72 men will take either leuprolide plus abiraterone acetate or relugolix …

This study compares a new, shorter radiation method (5 treatments over 2 weeks) to the usual longer course (20-45 treatments over 4-9 weeks) for men with high-risk prostate cancer. The goal is to see if the shorter schedule works just as well at preventing the cancer from spreadi…

This study tests two drugs, cabozantinib and atezolizumab, in 33 men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see if the combination can stop or shrink tumors. Participants must have non-measurable disease o…

This study tests whether high-dose vitamin D can prevent bone loss in men aged 50+ with prostate cancer who are receiving hormone therapy (ADT). ADT can weaken bones, raising the risk of fractures. Researchers will give 240 participants either high-dose vitamin D or a placebo for…

This study tests whether adding the drug talazoparib to standard hormone therapy can better control advanced prostate cancer that still responds to hormone treatment. About 70 men with cancer that has spread will receive the combination. The goal is to see if this approach lowers…

This study tests whether a new type of PET/MRI scan can accurately detect if prostate cancer has spread to nearby lymph nodes. About 50 men with high-risk prostate cancer who are scheduled for prostate removal surgery will receive the scan beforehand. The goal is to see if the sc…

This study tests whether adding cryoablation (freezing cancer cells) to standard radiation therapy provides better pain relief for people with cancer that has spread to their bones. About 40 adults with advanced cancers like prostate, kidney, or melanoma will be enrolled. The goa…

This study looks at why some prostate cancers become resistant to a targeted radiation treatment called 177Lu-PSMA. Researchers will take small tissue samples (biopsies) from tumors in 30 patients before and after therapy. The goal is to find genetic changes that cause resistance…